EARLY HEARING DETECTION AND INTERVENTION VIRTUAL CONFERENCE
MARCH 2-5, 2021
(Virtually the same conference, without elevators, airplane tickets, or hotel room keys)
9/25/2018 | 8:30 AM - 9:30 AM | Discussion Revisited: Is Universal Newborn CMV Screening Good Public Health Policy? | Emerald Ballroom I/II
Discussion Revisited: Is Universal Newborn CMV Screening Good Public Health Policy?
This will be a point-counterpoint panel exploring the pros and cons of universal CMV screening. Each participant will be given 4-5 questions in advance to prepare a one-minute answer. Following each prepared answer, one colleague may make a thirty-second response. The original presenter may respond for 30 sec. (10-15 minutes per question total, 4-5 questions)
- To understand the reasons for newborn screening for congenital CMV
- To understand how screening for congenital CMV infection conforms to current guidelines for newborn screening
Presentation:
This presentation has not yet been uploaded.
Handouts:
Handout is not Available
Transcripts:
CART transcripts are NOT YET available, but will be posted shortly after the conference
Presenters/Authors
Pablo Sanchez
(), pablo.sanchez@nationwidechildrens.org;
Dr. Sánchez is a neonatologist and pediatric infectious diseases specialist who has a longstanding interest in clinical and translational research focused on perinatal and neonatal infections and antimicrobial stewardship. He is currently a Professor of Pediatrics, in the Divisions of Neonatology and Pediatric Infectious Diseases and Director of Clinical & Translational Research (Neonatology) in the Center for Perinatal Research at Nationwide Children’s Hospital - The Ohio State University College of Medicine. He earned his medical degree at the University of Pittsburgh School of Medicine in 1981, as well as a fellowship in Neonatal-Perinatal Medicine from Columbia-Presbyterian Medical Center, New York, in 1986 and a fellowship in pediatric infectious disease from the University of Texas Southwestern (UTSW) Medical Center, Dallas, in 1988. He was on faculty at UTSW from 1986 to 2013. Dr. Sánchez is the principal investigator (PI) the National Institute of Child Health and Human Development (NICHD) Neonatal Research Network (NRN) at Nationwide Children’s Hospital – The Ohio State University. Previously, he served in that capacity while at UTSW from 2006-2013. He also served as the Dallas site PI for the National Institutes of Health National Institute on Deafness and Other Communication Disorders CHIMES study on congenital CMV screening and natural history of hearing loss in these infants and children. He has authored and co-authored more than 100 peer-reviewed publications and book chapters.
ASHA DISCLOSURE:
Financial -
Nonfinancial -
Kirstin Coverstone
(), kristin.coverstone@umn.edu;
Kirsten Coverstone is an audiologist with many years of service dedicated to early hearing detection and intervention. She grew up in southern Minnesota, earned her masters degree from the Univ. of Northern Iowa and her doctorate from Salus University. Kirsten has actively worked at the local state and national levels to promote universal newborn screening for hearing. As coordinator of the Lions Infant Hearing Program at the University of Minnesota she worked directly with hospitals to establish effective hearing screening programs and audiologists to confirm hearing loss. In addition, Kirsten implemented a statewide hearing instrument loaner program for infants and young children in Minnesota. She is dedicated to making a difference in the lives of children and their families as the MDH EHDI Screening Program Coordinator.
ASHA DISCLOSURE:
Financial -
Nonfinancial -
Fatima Kakkar
(), fatima.kakkar@umontreal.ca;
Dr Fatima Kakkar is a pediatric infectious diseases specialist and clinician-researcher in congenital infectious at Sainte-Justine University Health Center in Montreal, Canada, and Associate Professor of Pediatrics at the University of Montreal. Since 2017, she has co-directed the Women and Children’s Infectious Diseases Center “Centre d’infectiologie mère-enfant”, which provides care for infants affected by congenital infections in pregnancy. Her clinical and research
ASHA DISCLOSURE:
Financial -
Nonfinancial -
Sheila Dollard
(), sgd5@cdc.gov;
Sheila Dollard earned her PhD in Biochemistry from the University of Rochester Medical Center, Rochester NY.
She joined the Centers for Disease Control and Prevention in 1998 as Team Leader for Herpesvirus Diagnostics where her work has focused on HHV-8 (human herpesvirus 8) and CMV epidemiology and diagnostic assay development to meet U.S. public health needs.
ASHA DISCLOSURE:
Financial -
Nonfinancial -